Related by context. All words. (Click for frequent words.) 56 Chronic Myeloid Leukemia 55 Remissions 54 remission 53 Carcinoma 53 Follicular Lymphoma 53 Etanercept 53 Decitabine 53 CDAI 52 Myelodysplastic Syndrome 51 CR nPR 51 Sustained virologic response 51 DAS# remission 51 CRp 51 RECIST Response Evaluation Criteria 51 radiographic progression 51 Relapsed Refractory 51 mucosal healing 51 icatibant 51 virologic response 50 B Cell Lymphoma 50 moderate renal impairment 50 annualized relapse 50 Partial Response 50 Natalizumab 50 metastatic malignant 50 seropositive patients 50 Fludarabine 50 Diffuse Large B 50 Free Survival PFS 50 FOLPI 50 thrombocytosis 50 Relapses 50 Solid Tumors criteria 49 endoscopic remission 49 Response Evaluation Criteria 49 Cutaneous T 49 biochemical relapse 49 CCyR 49 ACR# response 49 DMARD 49 relapsing multiple sclerosis 49 Abatacept 49 Hydroxyurea 49 acute mania 49 Adjuvant therapy 49 ACR# responses 49 JAK2 V#F 49 MCyR 49 pCR 48 CIMZIA TM 48 leukemia AML 48 Mantle Cell Lymphoma 48 cytogenetic response 48 haematologic 48 T Cell Lymphoma 48 recurrent GBM 48 Infliximab 48 PegIFN RBV 48 CR CRu 48 FOLFOX6 48 8mg/kg 48 Cimzia TM 47 Trastuzumab 47 NMIBC 47 Acute Myeloid Leukemia 47 bortezomib refractory 47 sustained virologic response 47 IFN α 47 log# reduction 47 aripiprazole 47 progression TTP 47 achieved CCyR 47 relapsed MM 47 remissions 47 receiving golimumab 47 ritonavir boosted 47 Rituximab 47 Pemetrexed 47 complete cytogenetic 47 ABVD 47 HSCT 47 undetectable HCV RNA 47 remission CR 46 Scale EDSS 46 Adjuvant chemotherapy 46 FIRMAGON 46 4mg/kg 46 #mg/day [002] 46 decitabine 46 undetectable HBV DNA 46 PTLD 46 mg BID 46 nodular partial response 46 Acute Myeloid Leukaemia AML 46 cryptogenic 46 RECIST criteria 46 adjuvant tamoxifen 46 allogeneic transplantation 46 chemoradiation therapy 46 virological response 46 chlorambucil 46 stage IIIB 46 acute myeloid 46 cytogenetic responses 46 Scale EDSS score 46 E1 INT TM 46 Metastatic breast cancer 46 Imatinib 46 pT2 46 adjunctive placebo 46 ribavirin RBV 46 Doxil ® 46 metastatic hormone refractory 46 severe neutropenia 46 conventional DMARDs 46 viral kinetics 46 interferon ribavirin 46 detectable HCV RNA 46 refractory metastatic 46 Acute Myeloid Leukaemia 45 bladder carcinoma 45 ORAL HYCAMTIN 45 Exacerbations 45 polyarticular 45 Acute Myelogenous Leukemia 45 severe exacerbations 45 sustained virological response 45 methotrexate monotherapy 45 CLARITY study 45 mycophenolate mofetil 45 ara C 45 virological suppression 45 QTc intervals 45 AGILECT R 45 pelvic lymphadenectomy 45 remission induction 45 Glioblastoma Multiforme 45 BEACOPP 45 dasatinib 45 alfa 2a 45 plasma uric acid 45 biologic therapy 45 Myelodysplastic Syndrome MDS 45 APTIVUS r 45 Philadelphia Chromosome Positive 45 neurologic progression 45 FOLFOX4 45 HBeAg seroconversion 45 cis retinoic acid 45 ulcerative colitis UC 45 corticosteroid therapy 45 liver histology 45 5-FU/LV 45 biliary tract cancer 45 DOXIL 45 macroalbuminuria 45 fulminant 45 recovery CRp 45 parathyroidectomy 45 orchiectomy 45 severe oral mucositis 45 SJIA 45 LHRH agonist 45 #mg BID [003] 45 R0 resection 44 symptomatic intracranial hemorrhage 44 relapsed AML 44 rapid virologic response 44 refractory myeloma 44 complete remissions 44 EDSS score 44 peg interferon 44 visceral metastases 44 Aptivus ® 44 hematological parameters 44 FluCAM 44 leukemia ALL 44 anakinra 44 ACTEMRA TM 44 azacitidine 44 cell lymphoma CTCL 44 HER2 positive metastatic breast 44 cabazitaxel 44 lymphocytosis 44 cytoreduction 44 Glioblastoma Multiforme GBM 44 adalimumab Humira 44 chemoradiotherapy 44 partial remissions 44 gemcitabine Gemzar 44 splenectomized patients 44 CHOP chemotherapy 44 heavily pretreated patients 44 dose escalation phase 44 briakinumab 44 Stage IIB 44 neoadjuvant chemotherapy 44 Cisplatin 44 tumor lysis syndrome 44 immune thrombocytopenic purpura ITP 44 ASCT 44 keloid scarring 44 remitting MS 44 Non Hodgkin Lymphoma 44 eosinophilic asthma 44 virologic failure 44 mitoxantrone plus 44 pregabalin 44 pouchitis 44 comparator arm 44 PSADT 44 Traficet EN 44 Cell Lymphoma CTCL 44 cystectomy 44 follicular Non Hodgkin 44 IV NSCLC 44 deletion 5q 44 breast carcinoma 44 Major Depressive Disorder MDD 44 EDSS scores 44 follicular lymphomas 44 refractory AML 44 clodronate 44 neuroleptics 44 selegiline 44 AGILECT ® 44 CIMZIA ™ 44 achieved ACR# 44 measurable tumor regressions 44 systemic anaplastic large 44 estramustine 44 MACCE 44 anthracycline containing 44 COPAXONE ® 43 TACE 43 median PFS 43 baminercept 43 tipranavir 43 oral methylnaltrexone 43 tocilizumab 43 prostate cancer CRPC 43 octreotide LAR 43 evaluable patients 43 evaluable subjects 43 pramipexole 43 leukemia APL 43 differentiated thyroid 43 mitoxantrone 43 androgen deprivation 43 Waldenstrom Macroglobulinemia 43 huN# DM1 43 paclitaxel Taxol R 43 antiangiogenic therapy 43 MabCampath 43 metastatic renal cell carcinoma 43 unresectable stage 43 lymphadenectomy 43 generalized tonic clonic seizures 43 relapsed ovarian cancer 43 patients evaluable 43 previously untreated follicular 43 p#HER# positive 43 systemic corticosteroid 43 imatinib resistant 43 Hodgkin lymphoma HL 43 postoperative chemotherapy 43 DAPT 43 corticosteroid dexamethasone 43 alteplase 43 gastrointestinal stromal tumors GIST 43 elevated ALT 43 Zoledronic acid 43 Peginterferon alfa 2b 43 paclitaxel poliglumex 43 levodopa therapy 43 ALT flares 43 adalimumab 43 pegylated liposomal doxorubicin 43 interferon therapy 43 PEGylated interferon beta 1a 43 Bezielle 43 nephrectomy 43 plus methotrexate 43 neoadjuvant 43 visilizumab 43 doxorubicin cyclophosphamide 43 mCRC patients 43 nab paclitaxel 43 histologically confirmed 43 pretransplant 43 FOLFIRINOX 43 MGd 43 RLAI 43 RoACTEMRA 43 galiximab 43 cyclophosphamide methotrexate 43 relapsed Acute Myeloid 43 paliperidone palmitate 43 flutamide 43 Advagraf 43 alefacept 43 mycosis fungoides 43 taxane refractory 43 virologic suppression 43 RAPTIVA 43 immunosuppressive regimen 43 completely resected 43 androgen blockade 43 refractory SCLC 43 imatinib 43 DMARD therapy 43 erythropoietic 43 KRAS wild 43 neutrophil counts 43 Acute Myelogenous Leukemia AML 43 Flu Cy 43 Hepatocellular Carcinoma HCC 43 neoadjuvant treatment 43 Acute Lymphoblastic Leukaemia 43 GnRH agonist 43 C1 INH deficiency 43 alanine aminotransferase ALT 43 TNF antagonist 43 ACTEMRA 43 operable breast cancer 43 Acute Myeloid Leukemia AML 43 acute GvHD 42 clinically meaningful improvement 42 riociguat 42 hepatic encephalopathy HE 42 chemotherapy regimen 42 pomalidomide 42 surgically resectable 42 subcutaneous methylnaltrexone 42 androgen suppression 42 mesalamine granules 42 neutropenic patients 42 ipsilateral stroke 42 lipid lowering therapy 42 canakinumab 42 rituximab 42 refractory HL 42 Revlimid lenalidomide 42 mg/m2 dose 42 recurrent glioblastoma multiforme 42 Fludara 42 Gleevec resistant 42 daunorubicin 42 platelet inhibitor 42 non metastatic osteosarcoma 42 bone metastasis 42 locoregional recurrence 42 idarubicin 42 complete cytogenetic response 42 refractory indolent non 42 metastatic kidney 42 ACZ# 42 gemcitabine Gemzar ® 42 Acute Lymphoblastic Leukemia 42 peginterferon 42 allogeneic hematopoietic stem cell 42 leukemia CLL 42 nilotinib 42 cranial irradiation 42 underwent resection 42 Gleevec imatinib 42 undetectable viral load 42 mRCC 42 nonmetastatic 42 AVODART 42 myelodysplastic syndrome MDS 42 BRIM3 42 plus MTX 42 Bi Polar Disorder 42 lupus nephritis 42 stage IIIb IV 42 relapsed refractory 42 zoledronic acid 42 sinus rhythm 42 certolizumab 42 rimonabant #mg 42 chemotherapy docetaxel 42 mg kg dose 42 lenalidomide Revlimid R 42 MAGE A3 ASCI 42 Complete Response CR 42 EBRT 42 relapsing remitting 42 sulfasalazine 42 etanercept 42 ER CHOP 42 FOLFOX 42 adriamycin 42 darinaparsin 42 PASI scores 42 alkylating agent 42 ribavirin therapy 42 DFMO 42 MVax R 42 neointimal hyperplasia 42 IFN alfa 42 malignant lymphoma 42 Akt activation 42 Myelodysplasia 42 posttransplant 42 pemetrexed 42 5-fluorouracil/leucovorin 42 MBCT 42 ALND 42 Introgen ADVEXIN 42 rechallenge 42 underwent liver transplantation 42 samalizumab 42 mutated KRAS 42 colorectal carcinoma 42 lymphoma CTCL 42 pediatric acute lymphoblastic 42 chemoradiation 42 gout flares 42 chronic myeloid 42 liver metastasis 42 intermittent dosing 42 evaluable 42 CD# + [001] 42 epirubicin 42 Imiquimod 42 #mg BID [001] 42 cutaneous squamous cell carcinoma 42 adjuvant radiotherapy 42 resminostat 42 carboplatin paclitaxel 42 PegIFN 41 panobinostat 41 refractory CLL 41 advanced hepatocellular carcinoma 41 relapsed CLL 41 phase IIb study 41 basal cell carcinoma BCC 41 reperfusion therapy 41 ErbB2 positive 41 blastic phase 41 antiarrhythmic medications 41 CLL SLL 41 hypomanic episodes 41 vandetanib 41 LHRH agonists 41 relapsing forms 41 neoadjuvant therapy 41 axonal damage 41 Vidaza azacitidine 41 medically inoperable 41 Chronic Myelogenous Leukemia CML 41 taxane chemotherapy 41 localized renal 41 Ph + 41 LHRH analogues 41 chronic eosinophilic leukemia 41 gastrointestinal stromal tumors 41 #mg QD [002] 41 uric acid lowering 41 hormone refractory 41 lymphocyte count 41 cytopenias 41 adjuvant systemic 41 preoperative chemotherapy 41 imatinib therapy 41 infliximab 41 Mitoxantrone 41 cholinesterase inhibitor 41 interferon IFN 41 MDS AML 41 pulmonary dysfunction 41 K RAS 41 HbA1c levels 41 Recurrences 41 Acute myeloid leukemia 41 pathologic diagnosis 41 autoantibody positive 41 rufinamide 41 radical prostatectomy RP 41 remyelination 41 methotrexate therapy 41 rTMS 41 metastatic RCC 41 intravenous morphine 41 Acute Leukemia 41 viral suppression 41 seminomas 41 IFN gamma 41 nephrotoxicity 41 papillary renal cell carcinoma 41 dacarbazine DTIC 41 Non Hodgkin 41 tumor regressions 41 metastatic CRC 41 XR NTX 41 relapse 41 anthracyclines taxanes 41 adjuvant radiation 41 hematologic adverse 41 aprepitant 41 Glivec imatinib 41 pancytopenia 41 idiopathic thrombocytopenic purpura 41 KRAS mutant tumors 41 Herceptin trastuzumab 41 VGPR 41 abatacept 41 relapsed SCLC 41 dose melphalan 41 arsenic trioxide 41 pulmonary exacerbation 41 #mg/m# [002] 41 pT3 41 pancreatic adenocarcinoma 41 Paraplatin ® carboplatin 41 G CSF 41 dosage regimens 41 indolent lymphomas 41 hematologic toxicity 41 EXJADE 41 tolterodine 41 antidepressant therapy 41 metastatic renal 41 antibody MAb 41 pneumonectomy 41 thymoma 41 IRESSA 41 palliation 41 anthracycline taxane 41 chronic GVHD 41 adjuvant cisplatin 41 stage IIIb 41 lymphocytic leukemia 41 myeloproliferative diseases 41 antiandrogens 41 mg/m2/day 41 Interferon alpha 41 autologous transplants 41 Cetuximab 41 TEMODAL 41 Ph + ALL 41 androgen ablation 41 metastatic renal cell 41 IV melanoma 41 rapid virological response 41 recurrent NSCLC 41 refractory metastatic colorectal cancer 41 status epilepticus 41 external beam radiotherapy 40 urinary N telopeptide 40 chemo radiotherapy 40 lymph node dissection 40 doxorubicin HCl 40 abiraterone acetate 40 unresectable 40 gemcitabine cisplatin 40 RhuDex R 40 % CI #.#-#.# [007] 40 microtubule targeting 40 refractory NSCLC 40 essential thrombocythemia 40 bendamustine 40 ACR# [002] 40 hematologic 40 chemosensitivity 40 transplantation HCT 40 Hashimoto thyroiditis 40 Soliris therapy 40 pyrazinamide 40 diagnosed glioblastoma multiforme 40 relapsing remitting multiple sclerosis 40 cyclophosphamide chemotherapy 40 dose cytarabine 40 androgen suppression therapy 40 prednisone prednisolone 40 trabectedin 40 cilengitide 40 novel VDA molecule 40 response pCR 40 prior chemotherapy regimens 40 ovarian carcinoma 40 dyskeratosis congenita 40 Combination therapy 40 glufosfamide 40 Q#IR 40 vestibular schwannomas 40 FOLPI regimen 40 imatinib Gleevec 40 clinically localized prostate 40 lobular carcinoma 40 acute gout flares 40 childhood acute lymphoblastic 40 tumor shrinkage 40 concomitant medications 40 Intravenous CP 40 androgen depletion 40 Kinoid 40 anti leukemic 40 elacytarabine 40 lanthanum carbonate 40 refractory acute myeloid 40 dosing cohorts 40 titration phase 40 moderate renal insufficiency 40 urate lowering therapy 40 relapsing remitting MS RRMS 40 dosing intervals 40 fluorouracil 40 NLX P# 40 temozolomide 40 refractory indolent NHL 40 intensive statin therapy 40 Bevacizumab Avastin 40 cisplatin chemotherapy 40 myeloproliferative disorder 40 Cholangiocarcinoma 40 gastrointestinal stromal tumor GIST 40 electrical cardioversion 40 immune reconstitution 40 ciclosporin 40 relapsing remitting MS 40 myelogenous leukemia 40 discontinuations due 40 intravenous cyclophosphamide 40 advanced carcinoid 40 induce remission 40 telaprevir dosed 40 choriocarcinoma 40 gemcitabine carboplatin 40 heavily pretreated 40 myeloproliferative neoplasms 40 antithrombotic therapy 40 palifermin 40 FUSILEV enhances 40 low dose cytarabine 40 eculizumab therapy 40 clinicopathological features 40 trans retinoic acid 40 oral FTY# 40 CRu 40 immune thrombocytopenic purpura 40 reconviction 40 hematologic abnormalities 40 Chronic pancreatitis 40 debulking surgery 40 CYP #D# 40 activin 40 CD# mAb 40 erlotinib Tarceva ® 40 COPD exacerbations 40 torsade de pointes 40 IL 1ß 40 VELCADE melphalan 40 Hodgkin lymphoma NHL 40 paclitaxel cisplatin 40 superficial bladder cancer 40 bevacizumab Avastin 40 nadolol 40 autoimmune thyroiditis 40 dose titration 40 recurrent VTE 40 febrile neutropenia 40 docetaxel Taxotere ® 40 pamidronate 40 HERCEPTIN 40 nephritis 40 pazopanib 40 trastuzumab Herceptin ® 40 Vidofludimus 40 PSMA ADC 40 thyroiditis 40 #mg dose [001] 40 Interferon 39 castrate resistant 39 monotherapy 39 doxorubicin docetaxel 39 interferon alfa 39 seminoma 39 receiving VICTRELIS 39 BRCA deficient 39 refractory systemic ALCL 39 hematopoietic cancers 39 non progressors 39 platinum refractory 39 non splenectomized 39 myelofibrosis polycythemia vera 39 systemic mastocytosis 39 CsA 39 MS relapses 39 trastuzumab 39 immunosuppressive medications 39 autoimmune hemolytic anemia 39 acute myelocytic leukemia 39 5FU 39 endometrial hyperplasia 39 clinically meaningful improvements 39 Crohn disease 39 antiandrogen 39 ankylosing spondylitis AS 39 adalimumab etanercept 39 neoadjuvant radiation 39 anagrelide 39 pheochromocytoma 39 pleural mesothelioma 39 refractory Hodgkin 39 antiepileptic medications 39 androgen therapy 39 unfavorable cytogenetics 39 dacarbazine 39 HER2 positive breast 39 demonstrated antitumor activity 39 basiliximab 39 null responders 39 Waldenstrom macroglobulinemia 39 Torisel 39 HUMIRA adalimumab 39 metastatic malignant melanoma 39 allogeneic stem cell 39 HRPC 39 transgene expression 39 FOLFOX chemotherapy 39 folinic acid 39 HER2 negative 39 abiraterone 39 Median survival 39 MGUS 39 metastatic bone 39 docetaxel chemotherapy 39 relapsed 39 receiving highly emetogenic 39 Acute Lymphocytic Leukemia 39 weekly intravenous infusions 39 prior nephrectomy 39 resistant hormone refractory 39 pegfilgrastim 39 Chronic ITP 39 adverse cytogenetics 39 acute lymphoblastic 39 lymphopenia 39 RRMS patients 39 allogeneic HSCT 39 EGFR tyrosine kinase inhibitors 39 OvaRex MAb 39 moderately emetogenic 39 XGEVA 39 Relapsing remitting MS 39 diagnosed multiple myeloma 39 temsirolimus 39 indolent NHL 39 vismodegib 39 basal cell nevus syndrome 39 orchidectomy 39 myeloid leukemia 39 tumor resection 39 disease progression TTP 39 DMARDs 39 topotecan 39 untreated metastatic colorectal 39 aromatase inhibitor therapy 39 HNSCC 39 macroglobulinemia 39 relapsed acute myelogenous 39 irinotecan chemotherapy 39 graft dysfunction 39 adrenocortical cancer 39 superficial basal cell carcinoma 39 cytarabine daunorubicin 39 JMML 39 Ph + acute lymphoblastic 39 HBeAg positive patients 39 T1c 39 diffuse intrinsic pontine glioma 39 idiopathic thrombocytopenic purpura ITP 39 allogeneic transplant 39 thrombocytopenic 39 imetelstat 39 erosive esophagitis 39 radioiodine therapy 39 ELACYT 39 etoposide 39 anaplastic 39 romiplostim 39 LIALDA 39 relapsed APL 39 antitumour activity 39 adjuvant endocrine therapy 39 metastatic GIST 39 rtPA 39 lenalidomide dexamethasone 39 coinfected patients 39 mg simvastatin 39 carbidopa 38 cytopenia 38 carcinoid 38 papillary RCC 38 induction regimen 38 serologically active systemic lupus 38 anaplastic astrocytoma 38 hepatic metastases 38 natalizumab 38 pegylated interferon 38 chronic myeloid leukemia CML 38 cisplatin 38 Hypertensive adverse reactions 38 peritoneal carcinomatosis 38 P selectin 38 IV malignant melanoma 38 azathioprine 38 acute myelogenous 38 Kepivance 38 iniparib BSI 38 advanced epithelial ovarian 38 GISTs 38 ELOXATIN 38 autoantibody levels 38 Acute Leukaemia 38 achieve sustained virologic 38 chronic myelogenous leukemia CML 38 calcineurin inhibitor 38 post transplant lymphoproliferative 38 cutaneous melanoma 38 haematological 38 Imprisonment 38 weekly subcutaneous injections 38 thalidomide dexamethasone 38 LHRH receptor positive 38 myelofibrosis 38 relapsed refractory multiple myeloma 38 major depressive disorder 38 lung metastasis 38 activating mutation 38 relapsed leukemia 38 urothelial bladder cancer 38 Tarceva erlotinib 38 telomerase activity 38 Hurthle cell 38 surgical debulking 38 cytotoxic chemotherapy 38 #mg/m# [001] 38 glucocorticoids 38 gastrointestinal stromal tumor 38 activated partial thromboplastin 38 pancreatic carcinoma 38 cells PBMCs 38 acute promyelocytic leukemia 38 ispinesib administered 38 leukemic 38 BEXXAR therapeutic regimen 38 EGFR expressing 38 Hodgkin lymphomas 38 psychotic disorders 38 FOLFIRI alone 38 phase Ph + 38 symptom flare ups 38 intracranial hemorrhage ICH 38 repolarization 38 chronic idiopathic 38 myeloablative 38 E#F# 38 EGFR mutation positive 38 VT VF 38 Pegasys ® 38 Hodgkin Lymphoma 38 concomitant antibiotics 38 fibrinolysis 38 DMSA 38 immunomodulator 38 TRAIL induced apoptosis 38 non Hodgkin Lymphoma 38 cervical carcinoma 38 anaplastic thyroid carcinoma 38 curative resection 38 tumor recurrence 38 ductal cancer 38 achieved sustained virological 38 IV metastatic melanoma 38 MabThera Rituxan 38 Leber Congenital Amaurosis LCA 38 glatiramer acetate Copaxone 38 NMDA antagonist 38 seliciclib 38 electroconvulsive therapy 38 antithymocyte globulin 38 Pegasys plus Copegus 38 Median progression 38 lung metastases 38 placebo dexamethasone 38 refractory colorectal cancer 38 potent antiretroviral therapy 38 TORISEL 38 hypercalcemia 38 hepatic resection 38 achieved sustained virologic 38 PEGPH# 38 nephrotoxic drugs 38 pancreatic resection 38 TGF b 38 VIDAZA 38 sunitinib 38 antiretroviral naïve 38 Gleevec imatinib mesylate 38 RBC transfusions 38 prostate adenocarcinoma 37 erlotinib 37 gemcitabine chemotherapy 37 docetaxel 37 endothelin receptor antagonists 37 oral clodronate 37 oral prednisolone 37 hypoglycaemic episodes 37 alpha 2A adrenoceptor 37 antiarrhythmic drugs 37 recurrent malignant glioma 37 MIRCERA 37 refractory CTCL 37 phase IIb trial 37 paclitaxel Taxol ® 37 anthracycline therapy 37 VcMP 37 paclitaxel eluting stents 37 undetectable virus HCV 37 rituximab refractory 37 relapses 37 mcg albinterferon alfa 2b 37 WBPA 37 CMV infection 37 non squamous histology 37 L dopa 37 trial evaluating Prochymal 37 Seliciclib 37 ponatinib 37 Nephrotic Syndrome 37 efficacy endpoint 37 anastrozole 37 follicular NHL 37 virologic responses 37 CINV 37 disease progression 37 acute leukemias 37 ARHI 37 FOLFOX4 alone 37 localized prostate 37 transarterial chemoembolization 37 Stage IV 37 cell carcinoma 37 underwent surgical resection 37 atacicept 37 bowel resection 37 gemcitabine 37 fallopian tube carcinoma 37 maximal doses 37 metastatic bladder 37 Hodgkin Disease 37 nucleotide analogs 37 lamivudine 37 virologically 37 Myelodysplastic syndromes MDS 37 Platinol ® cisplatin 37 relapsed Hodgkin lymphoma 37 opioid analgesia 37 retransplantation 37 anti androgen 37 malignant pleural mesothelioma 37 hormone deprivation 37 talabostat 37 standard chemotherapy regimen 37 RBC transfusion 37 taxotere 37 castration resistant 37 pharmacokinetic characteristics 37 dose cyclophosphamide 37 antioxidant supplementation 37 nutlin 3a 37 dirucotide MBP# 37 antitumor immunity 37 Raptiva r 37 tamoxifen therapy 37 adjuvant chemotherapy 37 Surgical resection 37 BPH symptoms 37 serologically active SLE 37 6 mercaptopurine 37 resectable 37 colectomy 37 relapser 37 advanced nonsquamous NSCLC 37 postherpetic neuralgia 37 myelosuppression 37 TTF Therapy 37 situ LCIS 37 recurrent metastatic 37 Arsenic trioxide 37 chronic neuropathic pain 37 demethylation 37 hematological toxicity 37 anti TNFs 37 precancerous condition 37 exacerbations